Figure 7: Gilteritinib down-regulates CD30 surface expression in ALCL cells.
SU-DHL-1 cells were treated for 24 hours with indicated concentrations of gilteritinib and stained with anti-CD30-FITC along with respective isotype control antibodies. The CD30 positive cells were measured by flow cytometry. Columns represent the mean of three independent experiments; bars represent the SEM.